Entering text into the input field will update the search result below

Beam Therapeutics: This Technology Should Be Part Of Every Investor's Portfolio

Oct. 01, 2021 10:24 AM ETBeam Therapeutics Inc. (BEAM)CRSP, NTLA, VERV, EDIT, CRBU, GRPH14 Comments
EE Investing profile picture
EE Investing


  • Gene-editing companies are fighting for their share in a future multi-trillion dollar market.
  • BEAM has a great management team, the best gene-editing technology, and follows a very smart platform licensing approach and is therefore positioned to dominated that market.
  • Investing in Beam is very risky due to the company's very early stage, but the 100x potential of the stock makes it a great addition to almost everybody's portfolio.

Wissenschaftler ist Teil eines DNA-Moleküls ersetzen. Gentechnik und gen-Manipulation-Konzept.

vchal/iStock via Getty Images

Over the next decades, there will be a multi-trillion-dollar opportunity for gene-editing-based therapies. CRISPR-based technologies, especially base editing, have the best chance to capture a majority of that market. Because of a great management team, the best technology, and its licensing model, Beam Therapeutics (

This article was written by

EE Investing profile picture
My Background: Grew up in Germany, working and living in China. MSc in Finance. Years of experience in strategy consulting and finance.Stocks that I cover usually have market caps between $10M and $25B and fall into one of the two categories below:Category A - Asian stocks: I work and live in China, am able to speak Mandarin, and therefore can provide readers with unique insights. I believe especially Chinese stocks are extremely mispriced. Some companies are obvious scams and/or trade for far too high valuations, and some stocks are growing rapidly have P/E ratios of below 3 and are debt-free. Most of my profits I earn in this category. (recent examples are FINV, YRD, VIPS or HUYA)Category B - Growth at a reasonable price: As I do not want my whole portfolio to be exposed to Asia, I also analyze a lot of US stocks. My focus is on, often undercovered, growth companies that are in the best case already profitable and available for a reasonable price. (recent examples are PUBM, GPRO or MED)(Important Note: My articles and comments are not intended to be investment advice. Please do your own due diligence before making investments in any security.)

Analyst’s Disclosure: I/we have a beneficial long position in the shares of BEAM, CRSP either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.